Antimicrobial Efficacy of Cefoperazone-Salbactam Plus Tigecycline versus Cefoperazone-Salbactam Against Respiratory Pathogens and Their Effect on Laboratory Indices

• Published in: Pakistan Armed Forces medical journal 2023-07, Vol.73 (3), p.913-16
• Main Authors: Shaukat, Sundas, Irfan, Zona, Arif, Haseeba, Sadiq, Sidra, Bakhtiar, Shehnaz, Ismail, Muhammad
• Format: Article
• Language: English
• Subjects: Cefoperazone; Infections; Respiratory; Sulbactam; Tigecycline
• ISSN: 0030-9648; 2411-8842
• DOI: 10.51253/pafmj.v73i3.10546

Objective: To compare the antimicrobial efficacy of cefoperazone plus tigecycline versus cefoperzone and their effect on biochemical indices. Study Design: Quasi-experimental study. Place and Duration of Study: Department of Pathology, Rehman Medical Institute, Peshawar Pakistan, Nov 2022 to May 2023. Methodology: Patients of either gender with age >20 years having intensive care unit stay of >72 hours having clinical and radiological evidence of hospital acquired respiratory infection were included in the trial. A non-randomized convenience sampling technique was employed. Group CT patients received a combination of cefoperazone-sulbactam plus tigecycline intravenously while Group C participants received only cefoperazone-salbactam. Demographics, inflammatory markers,pathogens, treatment effectivity were recorded. Results: Mean age of participants in Group CT was 57.59±6.08 years as compared to 56.37±6.87 years in Group C. Pseudomonas aeruginosa was the most common pathogen identified in 30(23.8%) patients. CRP, WBC’s and PCT was significantly reduced after antibiotic treatment in both groups with a p-value of